GU Cancers 2025 | Optimizing ADC combinations in advanced bladder cancer
Terence Friedlander, MD, University of California, San Francisco, CA, discusses the rationale behind novel drug combinations involving antibody-drug conjugates (ADCs) in advanced bladder cancer. Pairing ADCs with complementary therapies, such as immunotherapy, chemotherapy or radiation, may enhance treatment efficacy. While clinical trials often take a generalized approach, Dr Friedlander emphasizes the need for a more strategic, patient-specific selection of ADC partners. By identifying the best combinations for different patient groups, researchers aim to optimize outcomes and refine treatment strategies for bladder cancer. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
